Spantide I TFA structure
|
Common Name | Spantide I TFA | ||
---|---|---|---|---|
CAS Number | 91224-37-2 | Molecular Weight | 1497.79000 | |
Density | N/A | Boiling Point | N/A | |
Molecular Formula | C75H108N20O13 | Melting Point | N/A | |
MSDS | N/A | Flash Point | N/A |
Use of Spantide I TFASpantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3]. |
Name | (D-ARG1,D-TRP7·9,LEU11)-SUBSTANCE P |
---|---|
Synonym | More Synonyms |
Description | Spantide I, a substance P analog, is a selective NK1 receptor antagonist, with Ki values of 230 nM and 8150 nM for NK1 and NK2 receptor, respectively. Spantide I provides an approach to reduce type 1 and enhance the type 2 cytokine IL-10 in the infected cornea, leading to a significant reduction in corneal perforation[1][2][3]. |
---|---|
Related Catalog | |
Target |
NK1:230 nM (Ki) NK2:8150 nM (Ki) |
In Vivo | Spantide I (50 and 100 nM perfused through the cerebral ventricles) causes a complete respiratory arrest in all of the examined animals[2]. Spantide I (36 μg/mouse, ip daily) significantly decreases the number of perforated corneas, bacterial counts, and PMNs. Spantide I also downregulates the mRNA levels for type I cytokines (e.g., IFN-γ) as well as MIP-2, IL-6, TNF-α, and IL-1β[3]. Animal Model: Female, 8-week-old C57BL/6 (B6) and BALB/c mice[3]. Dosage: 36 μg/mouse. Administration: IP on days -1 and 0 (day of infection) and daily through 5 days pi (post infection). Result: At 3 and 5 days pi, compound-treated mice had significantly less severe ocular disease than did the PBS-treated mice. Contained significantly fewer PMNs than the corneas of PBS-treated mice at 3 and 5 days pi. Significantly reduced levels of corneal TNF-α mRNA at 3 and 5 days pi. Significantly reduced the level of IL-18 mRNA at 1 day pi. |
References |
Molecular Formula | C75H108N20O13 |
---|---|
Molecular Weight | 1497.79000 |
Exact Mass | 1496.84000 |
PSA | 548.21000 |
LogP | 7.06100 |
Storage condition | -20°C |
Involvement of midbrain tectum neurokinin-mediated mechanisms in fear and anxiety.
Braz. J. Med. Biol. Res. 45(4) , 349-56, (2012) Electrical stimulation of midbrain tectum structures, particularly the dorsal periaqueductal gray (dPAG) and inferior colliculus (IC), produces defensive responses, such as freezing and escape behavio... |
|
Solution conformation of Substance P antagonists-[D-Arg1, D-Trp7,9, Leu11]-SP, [D-Arg1, D-Pro2, D-Trp7,9, Leu11]-SP and [D-Pro2, D-Trp7,9]-SP by CD, NMR and MD simulations.
Peptides 26 , 875-885, (2005) Substance P (SP) is an important neuropeptide involved in pain transmission and induction of inflammation. Its antagonists are being extensively investigated for their non-narcotic analgesic and anti-... |
|
Substance P stimulates late-stage rat osteoblastic bone formation through neurokinin-1 receptors.
Neuropeptides 41(1) , 25-31, (2007) Substance P (SP) is a widely distributed neuropeptide that works as a neurotransmitter and neuromodulator. Recently, SP receptors, particularly neurokinin-1 receptors (NK(1)-Rs) that have a high affin... |
M.W. 1497.80 C75H108N20O13 |
SPANTIDE |
1-Arg-7,9-Trp-11-Leu-substance p |
SPANTIDE HYDROCHLORIDE |
Spantide I |
Substance P-[D-Arg1,D-Trp7,9,Leu11] |